The Allegation Unveiled
LOS ANGELES, Oct. 17, 2024 /PRNewswire/ — Glancy Prongay & Murray LLP (“GPM”) gives notice to investors with significant losses, offering them the chance to take charge of a securities fraud class action lawsuit against Allarity Therapeutics, Inc. (“Allarity” or the “Company”) ALLR.
Key Dates and Deadlines
Class Period: May 17, 2022 – July 19, 2024
Lead Plaintiff Deadline: November 12, 2024
Investors aspiring to steer the course of the Allarity lawsuit as the lead plaintiff have the avenue to provide their contact information at www.glancylaw.com/cases/Allarity-Therapeutics-Inc/. Alternatively, they can reach out to Charles H. Linehan, at GPM via 310-201-9150, Toll-Free at 888-773-9224, or through email at shareholders@glancylaw.com to delve into the details concerning their rights.
The Alleged Misconduct
The complaint lodged during the Class Period suggests that the Defendants failed to intimate investors of certain crucial facts. These include the purported exaggeration of Dovitinib NDA’s regulatory prospects and improper conduct by Allarity and three former officers. The misdeeds in connection with the Dovitinib NDA and/or the Dovitinib-DRP PMA supposedly put the Company at a heightened risk of regulatory or governmental scrutiny and enforcement action, as well as potential legal, financial, and reputational repercussions.
Red Flags Disregarded
Furthermore, subsequent to Allarity’s disclosure of an ongoing investigation into misconduct concerning the Dovitinib NDA and/or the Dovitinib-DRP PMA, the Company downplayed the probability of facing enforcement actions. Consequently, the lawsuit posits that the upbeat statements made by Defendants regarding the Company’s business, operations, and future prospects were substantially misleading or lacking a solid foundation throughout the pertinent periods.
Stay Informed
To stay in the loop with developments regarding this class action, reach out to Charles Linehan, Esquire, of GPM, based in Los Angeles, California. Contact can be made through phone at 310-201-9150 or 888-773-9224, via email at shareholders@glancylaw.com, or by visiting their website.
